Research Focus Areas

Our clinical research has four main focuses:

  1. Identification of risk factors, exposures, healthcare disparities/SDOH, and environment interactions that lead to early childhood wheezing and severe asthma.
  2. Participation in NIH funded, multi-center asthma clinical trials in both preschool- and school-aged children.
  3. Participation in pharmaceutical trials to bring new pediatric asthma therapies to the market.
  4. Utilization of stakeholder input from patients, families, schools, community pediatricians, and medical providers to develop, implement, and test technology-based interventions for children with asthma.

Lab Projects (5)

Horizon Study

Study comparing tezepelumab to placebo in children ages 5 to 11 with a history of severe eosinophilic asthma. This study is funded by AstraZeneca.

TreKids Study

A study evaluating dupilumab versus placebo in children ages 2 to 5 years with a history of severe eosinophilic asthma. This study is funded by Sanofi.

FAROS Study

A study evaluating inhaled budesonide/glycopyrrolate/formoterol fumarate versus placebo in children ages 4 to 11 years with a history of moderate-to-severe eosinophilic asthma. This study is funded by AstraZeneca.

Preventing Asthma in High Risk Kids (PARK) Study

PARK study of omalizumab compared to placebo to reduce the diagnosis of childhood asthma in high risk 2-3-year-olds with a history of recurrent wheezing. This study is funded by the National Institutes of Health.

Oral Bacterial Extract (ORBEX) Study

ORBEX study of bronchovaxam compared to placebo to reduced the diagnosis of childhood wheezing and asthma in high risk 6-18-month-olds with personal or family history of allergic disease. This study is funded by the National Institutes of Health.